JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

# A Review on Smart Surface-Engineered Nanoparticles for Precision Drug Delivery

Shilpa Khambete*[1], Sudha Vengurlekar[2], Sachin Kumar Jain[3], Hemant Khambete[4]

[1] *Department of Pharmaceutics, Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India*
[2] *Department of Medicinal Chemistry, Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India*
[3] *Department of Pharmacognosy, Oriental College of Pharmacy, Indore, Madhya Pradesh, India*
[4] *Department of Pharmaceutics, Medicaps University, Indore, Madhya Pradesh, India*

Publication history: Received on 25th January 2026; Revised on 6th March 2026; Accepted on 7th March 2026

Article DOI: 10.69613/43dp2x31

**Abstract**: Precision medicine relies on the development of therapeutic systems capable of molecular-level manipulation. Traditional drug delivery remains restricted by poor bioavailability, rapid systemic clearance, and non-specific distribution, leading to adverse effects in healthy tissues. Surface-engineered nanocarriers address these hurdles through sophisticated functionalization strategies. Organic, inorganic, and carbon-based nanoplatforms provide versatile templates for encapsulation and controlled release. Functional layers, such as polyethylene glycol, establish a hydrated shield that prevents opsonization and extends circulation half-life. Integration of specific ligands including antibodies, peptides, and small molecules enables active targeting through receptor-mediated endocytosis, facilitating site-specific accumulation at diseased sites like solid tumors. Stimuli-responsive designs allow for triggered release in response to pathological environments, such as acidic pH or enzymatic overexpression. Specialized techniques like red blood cell hitchhiking and the recruitment of endogenous proteins allow for the traversal of the blood-brain barrier and pulmonary endothelium. Despite therapeutic potential, clinical translation is delayed by manufacturing complexities, batch-to-batch variability, and immunological responses such as accelerated blood clearance. Refining the nano-bio interface through biomimetic design remains essential for achieving consistent human clinical efficacy. Successful implementation of these smart platforms marks a significant shift toward personalized, patient-centric therapeutics, offering a clear path to minimize systemic toxicity while maximizing curative outcomes across various diseases.

**Keywords:** Nanotechnology; Precision Medicine; Surface Functionalization; Targeted Therapy; Biological Barriers.

## 1. Introduction

Conventional drug delivery systems (CDDS) face persistent challenges that restrict therapeutic efficacy and precipitate unintended adverse effects. A primary limitation involves the stochastic distribution of pharmacological agents throughout the systemic circulation, which leads to suboptimal concentrations at the intended site and collateral damage to healthy, unaffected tissues [1]. Inherent physicochemical properties of many therapeutic drugs, such as poor aqueous solubility and unfavorable pharmacokinetics, result in premature elimination or enzymatic degradation before reaching target receptors [2]. Conventional methodologies struggle to penetrate heterogeneous biological barriers, including mucosal layers and the highly restrictive blood-brain barrier (BBB). Consequently, only a negligible fraction of the administered dose typically reaches the intended anatomical site [3]. In the context of infectious diseases, the inability of standard antibiotics to effectively localize within bacterial niches has accelerated the emergence of drug-resistant pathogens [4]. Economic factors also play a role, as traditional drug development pathways are often characterized by prohibitive costs and extended timelines [5].

Nanotechnology offers a resolution to these complexities by providing precise control at the molecular level. Nanoparticles (NPs) serve as drug reservoirs, facilitating the controlled and sustained liberation of therapeutic agents to maintain optimal plasma levels and reduce dosing frequency [2]. Their diminutive size and high surface-to-volume ratio permit penetration of cellular membranes and the traversal of restrictive biological hurdles that typically impede conventional molecules [1,6]. These nanocarriers significantly improve the solubility of hydrophobic drugs and shield sensitive cargo, including proteins and nucleic acids, from degradative enzymes in the bloodstream, thereby enhancing the therapeutic index [4,6].

Surface engineering constitutes the fundamental mechanism for achieving precision in delivery. Unmodified nanoparticles are susceptible to rapid recognition by the mononuclear phagocyte system (MPS) and subsequent clearance. The application of "stealth" coatings, such as Polyethylene Glycol (PEG), creates a hydrated barrier that allows particles to evade immune detection and maintain

* Corresponding author: Shilpa Khambete

prolonged circulation [2]. Nanoparticles selectively bind to receptors overexpressed on target cells byconjugating specific ligands such as monoclonal antibodies, peptides, or folic acid such as those in malignant tissues [5,7]. Surfaces can be designed to respond to specific environmental triggers, including fluctuations in pH, temperature, or enzyme concentrations, ensuring that the payload is released exclusively within the diseased microenvironment [6,7]. Engineering the nano-drug biointerface allows particles to navigate complex environments, such as thick pulmonary mucus, to reach target cells effectively [8]. This analysis details the transition from non-specific administration to targeted precision therapies by investigating the design and engineering of diverse nanocarriers [1,2,3].

## 2. Classification of Nanoparticles in Drug Delivery

Nanoparticles are categorized based on their chemical architecture and material composition into three primary domains: organic, inorganic, and carbon-based systems [9,10].

### 2.1. Organic Nanocarriers

Organic platforms represent a significant class of biocompatible systems, primarily consisting of liposomes, micelles, and polymeric nanoparticles [6,11].

#### *2.1.1. Liposomes and Lipid-Based Systems*

Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous interior. This architecture facilitates the encapsulation of both hydrophilic agents within the core and lipophilic agents within the bilayer [3,8]. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) utilize solid lipids to provide enhanced physical stability and superior drug-loading capacity compared to traditional liquid-phase liposomes [6,8].

**Table 1. Classification of Nanocarriers by Material Composition and Performance**

| Nanoparticle Category | Types | Advantages | Typical Payload |
|---|---|---|---|
| Organic | Liposomes, Polymeric Micelles, SLNs | High biocompatibility; tunable degradation; biomimetic potential | Hydrophilic/lipophilic drugs, siRNA, mRNA |
| Inorganic | Gold (Au), Silver (Ag), Mesoporous Silica | Unique optical/magnetic properties; high surface area; thermal stability | Plasmonic agents, hydrophobic small molecules |
| Carbon-based | CNTs, Graphene, Fullerenes | High mechanical strength; excellent electrical conductivity; modular surface | Multifunctional ligands, diagnostic probes |
| Biological | RBC-EVs, Exosomes, Cell-membrane cloaked NPs | Natural "self" signaling; low immunogenicity; innate organ tropism | Sensitive biopharmaceuticals, proteins |

#### *2.1.2. Polymeric Micelles and Nanoparticles*

Polymeric micelles are self-assembled colloidal structures formed by amphiphilic block copolymers. They effectively sequester hydrophobic drugs within a central core to improve aqueous solubility [12,13]. Polymeric nanoparticles (PNPs) are derived from natural polymers like chitosan or synthetic variants such as poly(lactic-co-glycolic acid) (PLGA). These systems provide tunable degradation profiles and highly controlled release kinetics [1,6].

### 2.2. Inorganic Nanoparticles

Inorganic systems are characterized by distinct optical, magnetic, and electronic properties that offer multifunctional capabilities [14].

#### *2.2.1. Metallic and Mesoporous Silica Nanoparticles*

Metallic nanoparticles, particularly gold (Au) and silver (Ag), exhibit localized surface plasmon resonance (LSPR). This property is utilized in photothermal therapy and high-resolution diagnostics [10,14]. Mesoporous silica nanoparticles (MSNs) are valued for their ordered cylindrical pore structures, high specific surface area, and exceptional loading capacities [1,4].

*2.2.2. Quantum Dots and Ceramic Variants*

Quantum dots are semiconductor particles used for high-resolution fluorescent imaging. Ceramic nanoparticles provide heat-stable delivery options, ensuring the integrity of the payload under varying environmental conditions [8,10].

### 2.3. Carbon-Based Nanoparticles

This domain encompasses structures such as fullerenes (C60), graphene, and carbon nanotubes (CNTs) [8,9]. These materials possess exceptional mechanical strength, electrical conductivity, and high surface-to-volume ratios, supporting complex surface modifications for diverse biomedical applications [8,15]

## 3. Therapeutic Applications and Clinical Constraints

The integration of nanoparticle-based systems into drug delivery protocols provides significant pharmacokinetic advantages over conventional formulations. These benefits are primarily realized through the modulation of drug solubility and the protection of molecular cargo from physiological degradation.

### 3.1. Improvement of Pharmacokinetics and Bioavailability

A fundamental therapeutic benefit of nanocarriers is their capacity to improve the bioavailability of pharmaceutical agents with poor aqueous solubility [3,12]. These platforms shield sensitive cargo such as nucleic acids by functioning as molecular reservoirs, therapeutic proteins, and volatile phytochemicals from enzymatic degradation and the acidic conditions of the gastrointestinal tract [1,13,15]. Encapsulation permits a sustained release profile, maintaining therapeutic plasma concentrations for extended durations, which effectively reduces dosing frequency and improves patient adherence to treatment regimens [5,9].




**Figure 1. Comparison Pharmacokinetics and Therapeutic Window in Conventional Vs. Targeted Nanocarriers**

Precision is further enhanced through site-specific localization. Nanocarriers utilize the pathophysiological characteristics of solid tumors, such as the porous vasculature and impaired lymphatic drainage, for passive accumulation [12, 16]. Surface functionalization with specific ligands enables active targeting by facilitating binding to receptors that are disproportionately expressed on diseased cells [6,7]. This degree of precision minimizes the distribution of drugs to non-target organs, thereby reducing systemic toxicity and the collateral damage typically associated with conventional chemotherapy [8,11].

### 3.2. Biological Toxicity and Immune Recognition

Despite these advantages, several hurdles restrict the widespread clinical application of nanomedicines. Intrinsic toxicity is a primary concern; the high surface-to-volume ratio and diminutive scale of nanoparticles can lead to elevated cellular reactivity and the generation of reactive oxygen species (ROS) [10,17]. Evidence suggests that toxicity is frequently dependent on particle size and dosage, with particles smaller than 50 nm demonstrating an increased capacity for nuclear infiltration and potential genotoxicity [7,18].

The biological environment also facilitates opsonization. Upon entering the systemic circulation, unmodified nanoparticles are rapidly coated with plasma proteins, which serves as a signal for recognition and clearance by the mononuclear phagocyte system (MPS) [3,15]. While "stealth" modifications like PEGylation extend circulation time, they can trigger immunogenic responses or the development of anti-PEG antibodies in certain patient populations [6,7]. The complexity of the nano-bio interface often results in less than 1% of the administered dose reaching the intended target site in systemic applications [7].

**Table 2. Technical Bottlenecks and Potential Solutions in Nanomedicine**

| Clinical/Technical Challenge | Biological/Industrial Impact | Proposed Scientific Solution |
|---|---|---|
| Accelerated Blood Clearance (ABC) | Reduced efficacy upon repeated dosing | Alternative coatings (Poly-oxazolines); Zwitterionic polymers |
| Batch-to-Batch Variability | Inconsistent pharmacokinetics | Microfluidic-assisted assembly; Continuous manufacturing |
| Nanotoxicity (ROS generation) | Collateral cellular damage | Surface shielding with antioxidants; Biomimetic camouflaging |
| Spatiotemporal Specificity | Off-target payload release | Dual-stimuli responsive "AND" gate logic gates |
| Translational Gap | Animal models fail to predict human response | Organ-on-a-chip; AI-driven predictive modeling |




**Figure 2. Mechanism of Accelerated Blood Clearance (ABC)**

### 3.3. Manufacturing Challenges

From an industrial perspective, the production of sophisticated nanocarriers faces scalability and cost constraints. Achieving consistent batch-to-batch reproducibility and maintaining long-term physical stability specifically preventing particle aggregation requires advanced technology transfer [16,19]. Additionally, the absence of standardized regulatory frameworks for the quality assessment of nanomaterials creates a translational gap, as existing criteria for conventional molecular drugs are often insufficient for evaluating the unique physicochemical behaviors of nanoparticles [6,10,16].




**Figure 3. Manufacturing Pipeline involving Safety, Scalability, and Batch-to-Batch Consistency Checks**

## 4. Mechanisms of Surface Modification

Surface engineering is the primary strategy used to dictate the biological fate of nanocarriers and optimize their therapeutic index.

### 4.1. Passive Targeting and the Vascular Microenvironment

Passive targeting relies on the anatomical and pathophysiological features of the target tissue rather than molecular recognition [13,20]. The central mechanism for this approach is the Enhanced Permeability and Retention (EPR) effect. In solid tumors, the demand for oxygen and nutrients results in chaotic angiogenesis, producing a "leaky" vasculature with inter-endothelial gaps ranging from 200 to 800 nm [11]. Nanoparticles within the 10 to 200 nm range are sufficiently small to extravasate through these gaps and accumulate in the tumor stroma [8]. Because tumors often lack functional lymphatic drainage, these accumulated particles are effectively trapped, creating a localized drug reservoir [4,20].

The reliability of the EPR effect is a subject of ongoing investigation. Evidence indicates that passive accumulation is highly heterogeneous and influenced by tumor type, developmental stage, and local interstitial fluid pressure. Recent data suggest that active transendothelial transport, where endothelial cells actively ferry particles across the vessel wall, may be more significant for certain nanoparticle classes than simple passive leakage [7,21].

**Table 3. Stimuli-Responsive Surface Modifications for Triggered Release**

| Stimulus Type | Mechanism of Action | Material/Modification | Site of Action |
|---|---|---|---|
| pH-Responsive | Protonation/Deprotonation leading to swelling or disassembly | Poly(acrylic acid), Chitosan-PMAA | Tumor microenvironment (acidic); Endosomes |
| Redox-Responsive | Disulfide bond cleavage in reducing environments | Glutathione (GSH)-sensitive linkages | Intracellular space (high GSH concentration) |
| Enzyme-Responsive | Degradation of peptide/ester linkers by specific enzymes | Cathepsin B-sensitive peptides; MMP-cleavable shells | Inflammatory sites; Tumor stroma |
| Thermo-Responsive | Phase transition at Lower Critical Solution Temperature (LCST) | PNIPAM (Poly(N-isopropylacrylamide)) | Hyperthermic tumor regions; External heat application |
| ROS-Responsive | Oxidation-induced solubility change or bond cleavage | Boronic ester; Poly(propylene sulfide) | Sites of oxidative stress (Liver injury, Inflammation) |

### 4.2. Active Targeting via Molecular Recognition

Active targeting involves the functionalization of nanocarrier surfaces with ligands that recognize specific receptors overexpressed on target cells [6,13]. While passive mechanisms are responsible for the arrival of nanoparticles at the tissue site, active targeting drives cellular internalization [4,20]. This "lock-and-key" interaction initiates receptor-mediated endocytosis, allowing the therapeutic payload to bypass the cell membrane and reach intracellular targets [5,22].




**Figure 4. Surface Engineering and Targeted Drug Delivery of Nanocarriers**

#### *4.2.1. Ligand Selection and Specificity*

Folic acid (FA) is frequently utilized because folate receptors are significantly upregulated in various malignancies, including breast and ovarian cancers [6,17]. Carbohydrate ligands, such as galactose and N-acetylgalactosamine (GalNAc), are employed to target the Asialoglycoprotein Receptor (ASGPR) on hepatocytes for liver-specific interventions [22].

**Table 4. Comparison of Targeting Ligands and Their Biological Receptors**

| Ligand Class | Specific Example | Target Receptor/Marker | Associated Pathology |
|---|---|---|---|
| Small Molecules | Folic Acid (FA) | Folate Receptor (FRα) | Ovarian, Breast, and Lung Cancers |
| Carbohydrates | Galactose / GalNAc | Asialoglycoprotein Receptor (ASGPR) | Hepatocellular Carcinoma; Liver fibrosis |
| Peptides | RGD (Arg-Gly-Asp) | αvβ3 Integrins | Tumor Angiogenesis; Glioblastoma |
| Proteins | Transferrin (Tf) | Transferrin Receptor (TfR) | BBB traversal; highly proliferative cells |
| Antibodies | Trastuzumab (Herceptin) | HER2/neu | HER2-positive Breast Cancer |
| Nucleic Acids | AS1411 Aptamer | Nucleolin | Prostate and various solid tumors |

*4.2.2. Peptide and Antibody Conjugation*

Peptide sequences, such as RGD, are used to target integrins involved in tumor angiogenesis [1,20]. Monoclonal antibodies provide high specificity for receptors like HER2, although their large molecular weight can sometimes restrict deep tissue penetration [6,23]. Aptamers, which are single-stranded nucleic acids, are also utilized due to their low immunogenicity and high affinity for markers like the Prostate-Specific Membrane Antigen (PSMA) [5,20].

### 4.3. Polymer Encapsulation and the Stealth Effect

The application of advanced polymer coatings, primarily through PEGylation, is a fundamental strategy for circumventing innate clearance mechanisms [11]. Unmodified nanoparticles are subject to rapid opsonization, where serum proteins bind to the surface and mark the particles for sequestration by the MPS [17,23]. PEGylation involves the attachment of hydrophilic polyethylene glycol (PEG) chains to the nanoparticle surface, creating a protective hydrated layer [3,11]. This barrier sterically hinders the adsorption of opsonins, such as immunoglobulins and complement proteins, thereby extending the systemic circulation half-life [3,24].

The effectiveness of this "stealth" shield is determined by parameters such as the molecular weight and surface density of the PEG chains. Efficient shielding generally requires a molecular weight of at least 2 kDa [3,25]. At low surface coverage, PEG chains adopt a globular "mushroom" conformation, which may leave portions of the surface vulnerable. In contrast, high-density grafting forces the chains into an extended "brush" configuration, providing more comprehensive surface coverage and maximal suppression of macrophage uptake [26].

## 5. Physiochemical Modulation and Organ-Specific Localization

The optimization of pharmacokinetic profiles and cellular interactions depends heavily on the engineering of surface charge and the modulation of the hydrophilic-lipophilic balance (HLB). These parameters dictate the formation of the protein corona and the subsequent recognition of nanocarriers by the immune system.

### 5.1. Charge and Hydrophobicity Tuning

The electrical potential at the nanoparticle biointerface, characterized by the zeta potential, fundamentally influences colloidal stability and cellular internalization [14,27]. Nanoparticle systems demonstrate superior physical stability when they possess high absolute zeta potential values typically exceeding +30 mV or falling below −30 mV as the resulting inter-particle electrostatic repulsion prevents aggregation [28].

**Table 5. Influence of Zeta Potential on Nanoparticle Colloidal Stability and Bio-interaction**

| Zeta Potential Range | Colloidal Stability | Biological Interaction | Systemic Fate |
|---|---|---|---|
| > +30 mV | Excellent (Electrostatic repulsion) | Strong membrane adsorption; High uptake | High toxicity; Rapid MPS clearance |
| +10 to -10 mV | Poor (Risk of aggregation) | Minimal non-specific interaction | Extended circulation ("Stealth" behavior) |
| -10 to -30 mV | Moderate stability | Reduced cellular uptake | Good biocompatibility; Reduced opsonization |
| < -30 mV | Excellent stability | High repulsion from cell membranes | Sequestration by specific liver macrophages |

*5.1.1. Surface Charge and Membrane Interaction*

Cationic nanoparticles are frequently utilized to enhance intracellular delivery, as they facilitate strong electrostatic adsorption onto the negatively charged phospholipid bilayers of cell membranes [8,11]. However, an excessive positive charge often functions as a biological "alarm signal," leading to rapid recognition by the mononuclear phagocyte system (MPS) and potential systemic toxicity through membrane disruption [7, 29]. Consequently, neutral or slightly anionic platforms are often preferred for extending circulation half-life [7]. Precise charge modification, such as the sulfonation of cationic polymers like chitosan or the grafting of succinyl groups, is a proven method for enhancing biocompatibility [30].

*5.1.2. Hydrophobicity and Systemic Fate*

The degree of surface hydrophobicity is a primary determinant of a nanoparticle's systemic fate, as it dictates the rate of opsonization [3,17]. Hydrophobic surfaces are particularly susceptible to the adsorption of serum proteins, which marks the particles for immediate phagocytic clearance by macrophages in the liver and spleen [11,31]. While hydrophilicity is vital for systemic stability, a controlled degree of hydrophobicity is often required to facilitate the penetration of lipid-rich biological barriers. This balance is frequently achieved through amphiphilic architectures, such as the grafting of alkyl chains or cholesterol onto polymer backbones, promoting self-assembly where hydrophobic domains sequester the drug payload [1,13,24].

**5.2. Targeted Delivery to Major Organs**

One of the most significant challenges in precision medicine is ensuring the therapeutic payload reaches its intended destination while evading natural clearance systems.

*5.2.1. Hepatic Targeting and Endogenous Recruitment*

The liver is naturally predisposed to capture foreign particles, making it a primary site for nanoparticle accumulation [32]. Modern lipid nanoparticles (LNPs) utilize a sophisticated three-step process to reach liver cells. Once in the bloodstream, the nanoparticle sheds its protective PEG layer, exposing underlying molecules that recruit Apolipoprotein E (ApoE) from the patient's own blood [33]. This recruited protein acts as a biological "key" to unlock low-density lipoprotein receptors (LDL-R) on hepatocytes [33,34]. Additionally, Red Blood Cell-derived extracellular vesicles (RBC-EVs) are being investigated for their natural "liver tropism," which allows them to bypass standard immune signals [35].




**Figure 5. Organ-Targeting via Nano-Bio Interface Passkeys**

**Table 6. Strategies for Organ-Specific Delivery and Barrier Traversal**

| Target Organ | Major Biological Barrier | Engineering Strategy | Mechanism |
|---|---|---|---|
| Liver | Opsonization/RES Sequestration | Apolipoprotein E (ApoE) recruitment | LDL-R mediated hepatocyte uptake |
| Lungs | Mucus layer; Rapid clearance | RBC Hitchhiking; Cationic SORT lipids | Mechanical shear release; Vitronectin recruitment |
| Brain | Blood-Brain Barrier (BBB) | Receptor-mediated transcytosis ligands | Transferrin/Apolipoprotein mimicry |
| Infection Site | Bacterial Biofilms; Acidic niche | Charge-switchable surfaces (Negative to Positive) | pH-triggered electrostatic binding to bacteria |

*5.2.2. Pulmonary Delivery and the "Hitchhiking" Strategy*

A breakthrough technique known as Red Blood Cell (RBC) Hitchhiking involves attaching nanoparticles to the surface of circulating erythrocytes. As these cells transit through the narrow capillary beds of the lungs, mechanical shear forces release the nanoparticles directly into the pulmonary endothelium [35]. Researchers can redirect particles from the liver to the lungs via the recruitment of Vitronectin, by adding cationic lipids like DOTAP to LNPs, which binds to integrins in the pulmonary vasculature [33]. For

infections like bacterial pneumonia, charge-switchable nanoparticles are engineered to slip through thick mucus layers before flipping to a positive charge to penetrate bacterial biofilms [36, 37].

*5.2.3. Traversing the Blood-Brain Barrier (BBB)*

The BBB remains a formidable gatekeeper, excluding nearly 98% of small-molecule drugs [5,16]. To treat glioblastomas and neurodegenerative disorders, researchers are engineering systems that actively "tune" themselves for the neural environment [7]. This involves rational surface design to recruit specific proteins from the blood that facilitate transcytosis across the endothelial layer, expanding the reach of RNA interference (RNAi) and other biopharmaceuticals to the central nervous system [33,38].

## 6. Conclusion

The evolution of surface-modified nanoparticles has changed precision medicine from a theoretical standpoint into a viable clinical reality. Researchers have developed biological "passkeys" by engineering particles that can "hitchhike" on erythrocytes or recruit endogenous proteins to previously inaccessible therapeutic sites. These innovations demonstrate that the body's natural circulatory and immune systems, once viewed primarily as barriers, can be harnessed as effective partners in drug delivery. To achieve widespread success, future research must address manufacturing bottlenecks, specifically regarding batch-to-batch variability and long-term stability. Achieving true spatiotemporal specificity where payloads are released exclusively at the site of injury or infection will be the defining factor in minimizing systemic toxicity and maximizing patient safety. Combining advanced biomimetic designs with a deeper understanding of the nano-bio interface will be essential for the next generation of patient-centric nanomedicine.

## References

[1] Mikušová V, Mikuš P. Advances in Chitosan-Based Nanoparticles for Drug Delivery. Int J Mol Sci. 2021 Sep 6;22(17):9652.

[2] Yeh YC, Huang TH, Yang SC, Chen CC, Fang JY. Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances. Front Chem. 2020 Apr 24;8:286.

[3] Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, Tan WS. Stealth Coating of Nanoparticles in Drug-Delivery Systems. Nanomaterials. 2020 Apr 20;10(4):787.

[4] Kovtareva S, Kusepova L, Tazhkenova G, Mashan T, Bazarbaeva K, Kopishev E. Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs. Polymers. 2024 Apr 16;16(8):1105.

[5] Afzal O, Altamimi ASA, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials. 2022 Dec 19;12(24):4494.

[6] Anwar DM, Hedeya HY, Ghozlan SH, Ewas BM, Khattab SN. Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ J Basic Appl Sci. 2024 Oct 23;13(1):106.

[7] Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology. 2022 Aug 31;20(1):395.

[8] Yahya H, Hamza A, Anas M, Alvi SK, Farheen A, Alam M. An Extensive Overview of Nanoparticle Classification, their Applications and Emerging Horizons in Nanotechnology. Biosci Biotechnol Res Asia. 2025 Sep 30;22(3):936–53.

[9] Harish V, Tewari D, Gaur M, Yadav AB, Swaroop S, Bechelany M, et al. Review on Nanoparticles and Nanostructured Materials: Bioimaging, Biosensing, Drug Delivery, Tissue Engineering, Antimicrobial, and Agro-Food Applications. Nanomaterials. 2022 Jan 28;12(3):457.

[10] Eker F, Duman H, Akdaşçi E, Bolat E, Sarıtaş S, Karav S, et al. A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity. Molecules. 2024 Jul 25;29(15):3482.

[11] Campora S, Ghersi G. Recent developments and applications of smart nanoparticles in biomedicine. Nanotechnol Rev. 2022 Jul 11;11(1):2595–631.

[12] Bose A, Roy Burman D, Sikdar B, Patra P. Nanomicelles: Types, properties and applications in drug delivery. IET Nanobiotechnol. 2021 Feb;15(1):19–27.

[13] Rao TR, Sravani B, Aarthi R. Nanocarriers in Drug Delivery Systems: An Overview. J Adv Sci Res. 2025 Mar 15;16(03):8–14.

[14] Joudeh N, Linke D. Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists. J Nanobiotechnology. 2022 Jun 7;20(1):262.

[15] Vishwkarma H, Jain VK, Darwhekar GN. A comprehensive review on the classification, synthesis, characterization of nanopartices and their therapeutic impact. IP Int J Compr Adv Pharmacol. 2024 Oct 28;9(3):183–95.

[16] Wilar G, Suhandi C, Wathoni N, Fukunaga K, Kawahata I. Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects. Int J Nanomedicine. 2024 Nov;19:11357–78.

[17] Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles' Physicochemical Properties on Responses in Biological Systems. Polymers. 2023 Mar 23;15(7):1596.

[18] Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HAM, Abdelgawad MA, et al. Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges. Polymers. 2023 Feb 23;15(5):1123.

[19] Fritea L, Banica F, Costea T, Moldovan L, Dobjanschi L, Muresan M, et al. Metal Nanoparticles and Carbon-Based Nanomaterials for Improved Performances of Electrochemical (Bio)Sensors with Biomedical Applications. Materials. 2021 Oct 22;14(21):6319.

[20] Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019 Aug 1;71(8):1185–98.

[21] Dasgupta A, Sofias AM, Kiessling F, Lammers T. Nanoparticle Delivery to Tumours: From EPR and ATR Mechanisms to Clinical Impact. Pharmaceutics. 2024;16(2):224.

[22] Khambete S, Khambete H, Jain S. Galactose-Functionalized Solid Lipid Nanoparticles for Site-Specific Hepatic Targeting via the Asialoglycoprotein Receptor: Review Article. J Pharma Insights Res. 2025 Dec 5;3(6):206–13.

[23] Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules. 2020 May 8;25(9):2193.

[24] Herdiana Y, Febrina E, Nurhasanah S, Gozali D, Elamin KM, Wathoni N. Drug Loading in Chitosan-Based Nanoparticles. Pharmaceutics. 2024 Aug 6;16(8):1043.

[25] Younas A, Wang S, Asad M, Al Mamun A, Majeed S, Sharif A, et al. Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology. Mater Today Bio. 2026 Feb;36:102660.

[26] Roszkowski S, Durczynska Z, Szablewska S. Targeted nanodelivery systems for personalized cancer therapy. Rep Pract Oncol Radiother. 2025 Feb 19;29(6):776–88.

[27] Yang T, Zhai J, Hu D, Yang R, Wang G, Li Y, et al. "Targeting Design" of Nanoparticles in Tumor Therapy. Pharmaceutics. 2022 Sep 11;14(9):1919.

[28] Vagena IA, Malapani C, Gatou MA, Lagopati N, Pavlatou EA. Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives. Appl Sci. 2025 Mar 14;15(6):3189.

[29] Ly PD, Ly KN, Phan HL, Nguyen HHT, Duong VA, Nguyen HV. Recent advances in surface decoration of nanoparticles in drug delivery. Front Nanotechnol. 2024 Oct 11;6:1456939.

[30] Chen YN. Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis. J Clin Hepatol. 2025;11(2):45-58.

[31] Kumar V. Solid lipid nanoparticles based drug delivery for major infectious diseases: A narrative review. Nanotechnology. 2025;8:100228.

[32] Walia S, Mehta MJ. Recent progress on nanosystems for nucleic acid delivery. RSC Pharm. 2024;1(4):645–74.

[33] Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci. 2021 Dec 28;118(52):e2109256118.

[34] Endo EH, Makimori RY, Companhoni MVP. Lipid nanoparticles as a platform for RNAi delivery in central nervous system disorders. Nano Today. 2020;35:100987.

[35] Zhu K, Huang Y, Li K, Zhang K. Biomimetic erythrocyte-based drug delivery systems for organ-targeted therapy. Front Bioeng Biotechnol. 2025 Sep 9;13:1663092.

[36] Suman I, Klepac D, Vragović M, Križan H, Jäger E, Jäger A, et al. Targeted delivery of berberine via ROS-sensitive polymersomes enhances its hepatoprotective activity in CCl4-intoxicated mice. Nanoscale Adv. 2026;8(2):595–611.

[37] Tian Z, Zhang Y, Yun J, Kuang W, Li J. Advances in nanotechnology for the therapy of bacterial pneumonia. Front Cell Infect Microbiol. 2025 Jul 28;15:1639783.

[38] He Y, Yuan Y, Zhou M, Li M, Li L, Li C, et al. Development of siRNA therapeutics to combat microbial infections: a bibliometric analysis. Front Cell Infect Microbiol. 2025 Oct 24;15:1697880.